Pacific Edge Sets Trading Halt Ahead of Key U.S. Medicare Coverage Review for Cxbladder

An announcement from Pacific Edge Limited ( (PFGTF) ) is now available.

Pacific Edge has announced that its Medicare Administrative Contractor, Novitas, has scheduled a Contractor Advisory Committee meeting on 19 February 2026 U.S. Eastern Time to review evidence for urine biomarkers in patients with hematuria, a process expected to shape the language of any subsequent draft Local Coverage Determination for Medicare reimbursement of its Cxbladder tests. Given the potential impact of the committee’s opinions on reimbursement and market access for Cxbladder in the U.S., the company plans to place its shares in a trading halt ahead of the meeting, with trading expected to resume after it provides investors with an update before the New Zealand market opens on 23 February 2026.

Pacific Edge’s Cxbladder tests are designed to improve risk stratification and monitoring of urothelial cancer while enhancing clinical workflow efficiency and patient experience, and they are already used by thousands of urologists and accessible across several key geographies. The forthcoming Medicare coverage deliberations therefore represent a significant milestone that could further influence the company’s U.S. growth trajectory, support wider clinical adoption, and have material implications for patients, healthcare providers, and shareholders.

More about Pacific Edge Limited

Pacific Edge Limited is a global cancer diagnostics company specializing in non-invasive bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or undergoing surveillance for recurrent disease. Headquartered in Dunedin, New Zealand, it delivers its Cxbladder suite of genomic urine tests through CLIA-certified laboratories in New Zealand and the U.S. and has built a substantial clinical evidence base with broad adoption across multiple international markets.

Find detailed analytics on PFGTF stock on TipRanks’ Stock Analysis page.